May 27, 2026
Houston, TX – May 27, 2026 – Vivifi Medical, a medical device company focused on developing a minimally invasive, function-preserving treatment for benign prostatic hyperplasia (BPH), announced today that it has been selected to join the MedTech Innovator 2026 Accelerator Cohort. Vivifi Medical is one of only 65 companies—representing the top 4% of over 1,800 global applicants—chosen for this year's program.
MedTech Innovator (MTI) is the world's largest accelerator for medical technology startups. The highly competitive four-month program provides participants with world-class mentorship, strategic guidance, and access to a robust network of investors, providers, payers, manufacturers, and industry experts.
"We are honored to join this year's MedTech Innovator cohort. This opportunity gives us a powerful platform to validate our technology, build key partnerships, and accelerate our path to market." - Tushar Sharma, CEO of Vivifi Medical.
Vivifi Medical was selected based on its innovative, function-preserving approach to BPH, a condition affecting over 660 million men worldwide, its potential to address a critical unmet need in urology where existing treatments force patients to trade symptom relief for sexual and functional complications, and its alignment with MTI's mission to improve patient care through transformative technology.
Throughout the program, cohort companies will present at major industry events including The MedTech Conference powered by AdvaMed (October 18-21 in Boston) and/or the MedTech Strategist Innovation Summit (November 3-5 in San Diego), where they will compete for a share of $800,000 in funding.
In addition to joining the accelerator cohort, Vivifi Medical has been named to the 2026 MedTech Innovator Index, an exclusive recognition highlighting the most promising medtech startups selected through MTI's rigorous global review process. Inclusion on the Index underscores Vivifi Medical's position among the top emerging companies shaping the future of healthcare innovation.
About Vivifi Medical
Vivifi Medical is a Houston-based medical device company developing a minimally invasive, function-preserving treatment for benign prostatic hyperplasia (BPH). Founded to make BPH care simpler and more humane, Vivifi combines expertise in urology, vascular medicine, and device design to create solutions that respect patient anatomy and quality of life. The company is headquartered in Houston, TX with an office in Portland, OR, and is currently in clinical investigation to evaluate the safety and effectiveness of its technology. Vivifi is committed to partnering with clinicians and investors who share its vision of better outcomes and faster recovery for men with BPH.
About MedTech Innovator
MedTech Innovator is the world’s largest accelerator of medical device, digital health, and diagnostic companies. Its mission is to improve human health by accelerating the growth of companies transforming patient care. MTI has been a catalyst for groundbreaking healthcare solutions, sourcing over 20,000+ applicants and fostering the growth of 838 graduates. Alumni have collectively raised $12 billion in follow-on funding, achieved 63 acquisitions, and introduced 500+ products to the market, improving the health of millions worldwide. For more information about MedTech Innovator, its annual programs, portfolio of industry-leading startups, and insights on trends, visit MTI’s website, follow MTI on LinkedIn, and subscribe to its monthly newsletter.
Media Contact:
Tushar Sharma
CEO, Vivifi Medical
2450 Holcombe Blvd, Ste 1420, Houston, TX 77021* NOTE: This treatment is for investigational use only and is not approved by the FDA for commercial distribution. It is currently under clinical investigation to evaluate its safety and effectiveness.
